Product Introduction
Product Introduction
CJ-001 and CJ-002: Treatment of ED, ED with benign prostatic hyperplasia, pulmonary hypertension
CJ-001：Effective in 15 minutes, low dose, less side effects. GuangDong CJ Pharmaceuticals Co. develops 10mg and 5mg tablets. The 5mg tablet can treat ED and pulmonary
CJ-002：The nanocrystalline orally disintegrating tablet is a reformulated new drug. With the unique advantages of "quick effect + long-term effect", the drug takes effect within 15 minutes, which can shorten the waiting time for ED patients after taking the tablet, reduce the embarrassment and psychological pressure of patients, help restore the patient's confidence, and reduce the inferiority. The product has a long half-life of 36 hours. In addition to treat ED, it can also treat ED combined with benign prostatic hyperplasia. At the same time, the orally disintegrating tablet can solve the problem of swallowing difficulty in some patients, so as to further improve the medication compliance for the elderly and children.
Four new nanocrystalline drugs
| product code | Indications | Improvement advantage | Product Advantage |
|---|---|---|---|
| CJ-003 | Prostate cancer | Efficacy Compliance Safety | Excellent effect, no need to take the drug on an empty stomach. Reduce dose and side effects. |
| CJ-004 | Ovarian cancer Breast cancer | Safety Compliance | Lower dose and side effects. improve from BID to QD |
| CJ-005 | Lymphoma leukemia | Safety | Lower dose and side effects. Ahead of generic drugs for more than 7 years |
| CJ-006 | Prostate cancer resistance Diabetic Nephropathy |
Effectiveness | Overcome resistance of anticancer drugs |
CJ-007: First-in-Class Drug Product
“First-in-Class” drug products (domestic Type 1 drug product) are developed by Guangdong CJ pharmaceutical Co., Ltd, and characterized with high bioavailability, long half-life, and overcoming AR inhibitor resistance induced by genetic variations such as gene amplification, mutation and slicing variants (primary and secondary resistance).